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Biotherapeutic drugs, derived from biological molecules such as proteins and DNA, are 
becoming an integral and exceptionally critical aspect of modern medicine. Compared to 
common pharmaceutical drugs, biotherapeutics are much larger in size and have greater 
target specificity, allowing them to treat many chronic diseases ranging from cancer to 
rheumatoid arthritis. The major issue with protein based therapeutics is that they readily 
undergo proteolysis, or enzymatic degradation, when administered through subcutaneous 
injections. Traditionally, biotherapeutic modification procedures have centered on the use 
of PEG derivatives. This process, called PEGylation, is unfavorable due to the increases in 
molecular weights of the proteins and the heterogeneous mixture of products formed. 
Instead of PEG derivatives, we propose peptoids with N- methoxyethylglycine (NMEG) side 
chains to decrease proteolysis. NMEG groups are more advantageous than PEG derivatives 
due to their low molecular weight and ability to form homogeneous products. Our work 
focuses on increasing the protease resistance of target biotherapeutic proteins by cross-
linking a NMEG-5 peptoid to a cytochrome c via reductive amination. In the presence of a 
reducing agent, an imine bond is formed through the reduction of the peptoid’s aldehyde 
group and cytochrome c’s primary amine groups. Due to the expensive and unstable nature 
of commercially available aldehyde side chains, a green chemistry method, using only 
sodium hypochlorite (bleach) and 2,6,6-Tetramethylpiperidinoxy (TEMPO, free radical), 
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Biotherapeutic drugs derived from biological molecules are becoming an integral, and very 
critical aspect of modern medicine. The term “biotherapeutics” can represent a large class 
of treatments that are produced from cytokines, growth factors, hormones, antibodies, and 
other regulatory proteins or peptides [1, 2]. These therapeutics are typically produced or 
extracted using genetically engineered bacteria, yeast, fungi, and other cell types [3]. 
Biotherapeutic drugs have been used for decades to help treat multiple pathophysiological 
illnesses including cancer, hemophilia, infectious diseases, inflammatory and autoimmune 
diseases, and other rare diseases [4, 5, 6]. These larger biotherapeutic drugs are 
significantly favored over common pharmaceuticals due to their increased size, advantages 
in target specificity, and non-toxicity factors within the body [7]. The first biotherapeutic 
drug, high-quality human insulin, was derived from recombinant DNA and produced by Eli 
Lilly in 1982 [8]. Since, over 150 biotherapeutic medicines have been developed to improve 
treatment options and patient quality of life [9]. These advancements are critical in 
improving the accuracy and effectiveness of current treatment methods. For instance, since 
the 1970’s the 10-year survival rate of cancer patients has nearly doubled from one in four 
patients to one in two patients [10]. Although drastically increased, it leaves room for 
further improvement, ultimately opening the door for research and the eventual use of 







1.1. Biotherapeutic Proteins 
 
 
The use of proteins as potential biotherapeutic agents is gaining interest at an intriguing 
rate. In recent years, many distinct proteins have been discovered, and can be linked to the 
underlying mechanistic pathways of several common diseases. Researchers have estimated 
that between 25,000 and 40,000 functional genes that code for these proteins have been 
discovered within the human genome [11]. Using alternative splicing of genes and 
posttranslational modifications of proteins, these human genes have the potential to code 
for the distinct proteins that are being found within disease mechanisms [12, 13, 14]. 
Biotherapeutics are typically classified into three main groups of proteins, based on their 
physiological properties and course of treatment. The first group is made up of peptides 
and small protein therapeutics including growth factors, hormones, and cytokines [15]. 
Two current therapeutics within this class are Epogen®, a form of erythropoietin protein 
commonly used to increase the body’s production of red blood cells in anemia patients, and 
Neupogen®, a protein used to boost the body’s production of white blood cells for 
neutropenia patients [16, 17].  
 
The second group consists of non-immune therapeutic proteins including replacement 
enzymes, blood factors, anticoagulants, and other recombinant proteins [15]. The FDA 
approved drug Myozyme uses a recombinant human α-glucosidase enzyme for treatment 
in patients with Pompe Disease, an autosomal recessive myopathy that causes an abnormal 
storage of glycogen in tissues, resulting in premature fatalities [18, 19]. Tissue plasminogen 
activator (t-PA), one of the only successful treatment options for ischemic stroke victims, 
falls under this class of biotherapeutics. The naturally occurring protein, t-PA, serves as an 
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anticoagulant by converting the inactive proenzyme plasminogen into an active serine 
protease plasmin. In 1980, t-PA was first identified in melanoma cells, and later scientists 
were able isolate and purify the protein, creating today’s biotherapeutic [20].  
 
The third class of biotherapeutic proteins includes therapeutic antibodies and Fc-like 
fusion proteins. Monoclonal antibodies (mAbs) have shown great success as 
biotherapeutics for the treatment in autoimmune diseases due to the robust and flexible 
nature of the immunoglobulin molecule and their highly specific antigen-binding 
capabilities [15]. Immunoglobulin G (IgG) serves as one of the main types of antibodies 
found in the blood and extracellular fluid, functioning as a control mechanism for infections 
within body tissues. Antibodies and Fc-like fusion proteins serve as practical and viable 
means for the treatment of cancers, autoimmune, and inflammatory diseases [21, 22]. All 
three classes of biothereapeutic proteins provide excellent insight into the future of 
medicine, thus many pharmaceutical and biotechnology companies are investing 
substantial resources for their discovery and development. However, as promising as these 
drugs may be, there are still limitations in the mode of action, manufacturing and 
characterization techniques, and drug delivery methods.  
 
1.2. Biotherapeutic Drug Delivery  
 
 
Although biotherapeutic proteins have proven successful as treatment options for various 
diseases, there are still complications with delivery. Traditional routes, including oral, sub 
mucosal (nasal), parenteral (injection), and transdermal (through the skin) [23], are not 
feasible due to enzyme degradation and low absorption efficiency [24]. The oral delivery of 
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biotherapeutic proteins faces issues with poor absorbance within the gastrointestinal 
system and chemical degradation due to harsh enzymes within the digestive system, 
resulting in the loss of activity and function [25]. Proteins are extremely sensitive, where 
even the smallest change in conformation can cause a complete loss of function [26]. It is 
important to note that the pH within the colon and ileum is much higher than any other 
region in the GI tract, so difficulties arise when developing pH-controlled therapeutics. 
These pH-sensitive drugs are prone to degradation within the colon’s harsh environment 
[27].   
 
Nasal drug delivery is of interest due to the high vascularity and permeability within the 
nasal mucosa [28, 29]. These desirable characteristics stem from the nasal cavity’s large 
surface area, porous endothelial membrane, and highly vascularized epithelium [30]. Nasal 
drug delivery may be great for small molecules, but issues arise with high molecular weight 
compounds (above 1 kDa). There are also volume limitations in that the volume per dose 
that can be permeated across the membrane is restricted to 25-200 microliters [31]. As 
seen with other delivery methods, the body’s immune defense mechanism bodes an even 
bigger issue. Mucocillary clearance is the most important physiological defense mechanism 
inside the nasal cavity. If the biotherapeutic causes any irritation in the nasal mucosa, then 
this mechanism will cause the drug to be rapidly diluted, increasing the clearance by 
forming nasal mucus that will be eliminated from the nose [32].  
 
Subcutaneous injections and transdermal administration routes are challenging due to 
immunogenic potential and unwanted immune responses [33]. It has been reported that 
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subcutaneous degradation occurs with protein-based drugs due to the lymphatic transfer 
of these proteins when delivered parenterally [34]. The lymphatic system directly affects 
the absorption and distribution of therapeutic proteins after administration through T-cell 
responses initiated by skin-derived dendritic cells [35]. No matter the delivery route, any 
introduction of a foreign protein into the body has the potential to illicit an immune 
response, triggering the production of antibodies. The immune system is extremely 
sensitive, in that it can detect three-dimensional structural differences between the 
proteins native to the body and those being introduced [36]. For this reason, drug delivery 
systems and post-translational modifications are growing in interest to combat the 
immunogenicity issues of protein therapeutics.  
  
Currently, most drug delivery systems (DDS) are within the colloidal size range (1-
1000nm), and act to release the drug at a controlled rate for a prolonged period of time 
[37]. The drug is typically kept within a solid inner matrix that is layered by a permeable 
outer polymeric membrane through which the drug diffuses [38]. Research efforts have 
been focused on three main classes of DDS, including nanoparticles, liposome and other 
lipid-based carriers, and polymer-drug conjugates [39]. Poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles are attractive as DDSs due to their biodegradability and biocompatibility, 
FDA approval in parenteral administration systems, well-described production and 
characterization methods, protections from drug degradation, sustained release 
capabilities, possibility to modify surface properties, and target specificity for desired 
organs or cells [40]. The ability to modify surface properties is an important property in 
combatting cellular immune response and increasing cellular uptake of the drug. Surface 
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charge plays a major role in the interaction of the DDS with the cell. Studies have shown 
that positive charged nanoparticles allow a higher extent of cellular uptake due to the ionic 
interactions with the negatively charge cell membrane [41, 42, 43]. Despite these desirable 
properties, PLGA-nanoparticles have their limitations when dealing with certain protein 
therapeutics. The synthesis process of these nanoparticles involves factors and processes 
that may destabilize the proteins. When loading the protein into the nanoparticle, a double 
emulsion method is currently required leading to the aggregation of most proteins. 
Depending on the hydrophilicity of the protein, interactions between PLGA and the protein 
may also lead to the denaturing and aggregation of proteins [44]. It has been shown that 
immunogenicity can be minimized by ensuring stability, while limiting the formation of 
higher molecular weight protein aggregates [45]. Another issue associated with the use of 
nanoparticles is the complexity of cellular uptake and the unknown stability and 
cytotoxicity of the nanoparticles following metabolism. Evidence proves that the exocytosis 
of nanoparticles is drastically slower than endocytosis, but there is little information on the 
metabolism and long-term effects of these particles [46, 47].  
 
Of the three main classes of drug delivery systems, liposomes and lipid-based carriers have 
already had a major impact on targeted therapeutic protein delivery. Liposomes are 
defined as phospholipid vesicles consisting of multiple lipid bilayers enclosing discrete 
aqueous spaces [48]. Liposomes and lipid-based carriers are advantageous as drug delivery 
systems due to their biocompatibility, ability to self-assemble, extended drug circulation 
time, and their ability to carry multiple drugs at once [49]. Unlike PLGA-nanoparticles, 
liposomes possess the ability to encapsulate both hydrophilic and hydrophobic protein 
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drugs. Hydrophilic protein therapeutics can be trapped in the aqueous center, and 
hydrophobic proteins can be encapsulated in the bilayer membrane [50]. Water-soluble 
drugs can be loaded onto the liposome or lipid carriers through passive or active loading, 
depending on the functional groups and chemical environment. Passive loading, involving 
the formation of liposomes within an aqueous solution of the drug is the simplest, but least 
efficient method due to the limited loading capacity and waste of solution [51]. Active 
loading is more efficient, taking advantage of the pH difference between the external and 
internal liposome environments to allow the passage of drugs with charged functional 
groups through the membrane. Non-water soluble drugs can be incorporated directly into 
the membrane of the liposome or lipid-carrier; however, the drug to lipid ratio of the 
membrane is important to the dexterity of the liposome [52, 53]. For anticancer drugs, the 
antitumor efficacy is directly related to the drug release rate, and previous research 
demonstrated that by varying the drug to liposome ratio, optimal drug release rates could 
be achieved [54]. However, as with other therapeutic drug delivery methods, liposomes 
and lipid-carriers are still susceptible to enzyme degradation and macrophages, primarily 
in the spleen and liver. Therefore, to be used as treatment options for cancer and 
inflammatory diseases (inflammatory bowel disease, rheumatoid arthritis, etc) it is 
important to develop long-circulating liposomes that avoid the reticulo-endothelial system 
(RES) [55]. To achieve this passive drug delivery, liposomal surface modifications must be 
made to provide a steric boundary to the liposome that prevents RES uptake and blocks 
degradative enzymes from attaching [56, 57]. The use of ganglioside, GM1, to modify the 
liposome surface created “stealth” liposomes that were not readily taken up by the RES; 
ultimately, allowing the carrier to stay in circulation for a longer period of time [58]. A 
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second modification method, PEGylation, utilizes the addition of polyethylene glycol (PEG) 
groups onto the liposomal membrane surface to drastically improve the carrier’s 





Since the 1970’s, polyethylene-glycol (PEG) has been a highly-investigated polymer for the 
attachment and modification of biological macromolecules for multiple pharmaceutical 
applications. PEGylation is the covalent or noncovalent attachment of PEG polymers to 
macromolecules, most typically peptides, proteins, and antibody fragments [60]. Each 
individual PEG exemplifies many desired characteristics, including the absence of toxicity 
and immunogenicity, high water-solubility, and low mass-dependent elimination from the 
kidney [61, 62, 63]. Once conjugated, PEG sterically shields the protein’s surface from 
degradative agents and RES uptake, decreasing the protein’s immunogenic response, thus 
improving body-residence time. Along with the shielding effect, the increased molecular 
weight of the PEG-protein conjugate is advantageous in reducing renal clearance and 
altering biodistribution, also improving the residence time [64]. Renal clearance works by 
selectively filtering blood components through the glomerular filtration barrier (GFB). The 
GFB’s permeability is often dependent on the size and charge of the blood components [65]. 
While most proteins are selectively retained in the blood by the GFB, certain low molecular 
weight proteins and degraded protein fragments can undergo rapid renal clearance [66, 
67]. Thus, by increasing the protein’s molecular weight and improving the resistance to 
degradative agents in the body, PEGylation serves as a viable modification method for 
prolonging the body-residence time of potential therapeutic proteins [68].  
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Initially, researchers were skeptical that PEG could to be attached to large molecular 
weight proteins while maintaining biological activity; therefore, they directed their work 
solely on catalase and bovine serum albumin. For both molecules, PEGylation enhanced 
circulation times and eliminated immunological responses, while ultimately maintaining 
optimal protein activity and structural integrity [69, 70]. From these results, the efficacy of 
PEGylation in improving therapeutic drug delivery was deemed successful, sparking 
interest to further develop new PEGylated macromolecules. Since then, new methods for 
PEG conjugation have been introduced resulting in a wide array of macromolecules that 
can potentially be modified. To attach PEG to a molecule, it is important to functionalize 
one or both PEG termini with a functional group that is chosen based on the reactive group 
on the molecule being PEGylated. Amine conjugation, considered first-generation PEG 
chemistry, is the most common technique for the attachment of PEG molecules to proteins 
[71]. Amine reactive PEG derivatives form secondary amine linkages by substituting with 
multiple nucleophilic amino acid groups (lysine, serine, tyrosine, cysteine, and histidine) 
found in the protein, thus forming a heterogeneous mixture of PEG-protein conjugates [72]. 
First-generation PEG chemistry methods were first referred to as “gentle chemistry” due to 
the mild reaction conditions and use of simple, linear PEG molecules [73]. This simplicity, 
however, is important in maintaining the activity and three-dimensional structure of 
proteins. As previously mentioned, proteins are extremely sensitive to their environment, 
so it of utmost importance to limit the amount of harsh chemical used during conjugation.  
 
Second-generation PEGylation methods refer to any newly developed method of PEG 
conjugation that typically uses more complex PEG derivatives and harsher chemical 
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conditions than first-generation methods. These PEG derivatives, unlike the linear amine 
derivatives used in first-generation chemistry, contain multiple different functional groups 
such as aldehyde, carboxylic acid, and thiol groups [74, 75]. Depending on the desired 
product and degree of PEGylation, altering the chemical environment for most of the 
second-generation PEG derivatives creates a more site-specific PEGylation method. For 
instance, by changing the pH of the environment to acidic, mPEG-priopionaldehyde, a PEG 
derivative containing a reactive aldehyde group, selectively reacts with a protein’s N-
terminal α-amine, because nucleophilic substitution will only occur when the pH of the 
molecule is near the residue’s pKa [76, 77].  
 
1.3.1. Complications with PEGylation 
 
 
Since the 1970’s, concrete evidence has proven PEGylation as a viable manipulation 
method to improve pharmacokinetic properties of biotherapeutic proteins. PEG-protein 
conjugates display the “stealth” properties that are desired for the optimal drug 
deliverance of biotherapeutic agents [78]. PEGylation allows for the therapeutic protein to 
“sneak” by the body’s immune system by sterically shielding the protein’s surface from 
degradative agents, while also maintaining the water solubility and protein activity needed 
to be a viable treatment option [79]. Although PEGylation seems to be an ideal 
manipulation method, several limitations arise during the characterization and purification 
processes for these newly formed conjugates. First-generation PEGylation relies on the 
coupling of PEG derivatives to different reactive amino acids on the protein. Most 
therapeutic proteins rely on non-specific PEGylation occurring through the between 
hydroxyl- or aldehyde- functionalized PEG monomers and amine groups found on lysine 
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side chains or the N-terminus of the protein [80]. This coupling method, although highly 
reactive at physiological conditions, occurs at random positions, ultimately producing a 
heterogeneous mixture of PEG-conjugates. Since lysine makes up nearly 10% of all protein 
amino acids, it is incredibly difficult to characterize exactly which and how many lysine 
residues on the protein were PEGylated. These heterogeneous PEG-protein conjugates, 
called “isomers”, differ in molecular weights, protein stabilities, and even in the level of 
activities [81]. In 2003, the PEGylation of INF-α2a produced nine different isomers, each 
differing in the level of bioactivity. The difference in bioactivity of these isomers was 
theorized to directly affect the interferon receptor binding kinetics and stabilities [82]. The 
heterogeneity of PEG-protein conjugates lowers molecular activity of the therapeutic 
protein causing variations in treatment mechanisms and clinical side effects [83]. For FDA 
approval of non-site specific PEGylated protein drugs, the individual PEG-protein 
conjugates must be fully characterized, and biological analyses must be run on each 
conjugate to determine their pharmacodynamic properties. The more homogenous the 
product is, the better chance it has at getting approved by the FDA [63]. To achieve a 
homogeneous PEG-protein conjugate, site-specific coupling or effective purification 
methods must be incorporated. Purification methods are not only costly, but are inefficient 
and difficult as well. The purification will need to separate three molecules (PEG, PEG-
protein, native protein), where the separation of PEG and native protein is simple, using 
filtration and size-exclusion methods [84]. Difficulties arise when trying to isolate the 
desired PEG-protein conjugate from the others due to similar characteristics between the 
conjugates. As a result, several different methods, such as Ion Exchange Chromatography 
and Hydrophobic Interaction Chromatography, are completed in succession to fully purify 
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the product [85]. With consideration to the high manufacturing costs associated with the 
current production of therapeutic proteins, the production and purification of PEGylated 
proteins is economically infeasible. The overall process to achieve a high purity product is 
at the direct expense of high yield. To make up for the loss in yield, protein production will 
need to be increased, ultimately driving up manufacturing costs exponentially. Therefore, 
the more homogeneous the PEG-protein conjugate product formed, the less purification 
needed, decreasing the amount of protein lost, while improving the cost of manufacturing.  
 
To combat the heterogeneity issues with amine-coupling (first generation) researchers are 
developing second generation PEGylation methods that are focused on a more site-specific 
coupling of PEG derivatives to amino acids on the protein. The attachment of PEG to the 
thiol group of cysteine is considered site-specific because it accounts for only 1% of the 
total amino acid content in proteins. However, many of these cysteine groups will undergo 
disulfide bonding with each other, lowering the number of active thiol groups suitable for 
PEGylation. The undesired bonding between cysteine residues results in very few proteins 
possessing active cysteine groups capable of reacting with PEG monomers. To fix this 
dilemma, researchers are interested in introducing site-specific cysteines to the protein 
sequence through genetic engineering, but little is known regarding the effect this will have 
on protein activity [86]. Various other amino acids and functional groups have been of 
interest for second generation PEGylation, but most, if not all, have limitations that void 
them as suitable coupling agents. For instance, arginine is another amino acid that is less 
abundant than lysine, but has similar reaction chemistry involving the coupling of PEG to 
an amine group. Based on these two parameters, one could assume it to be a perfect option 
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for site-specific PEGylation producing an active, monodisperse PEG-protein conjugate. 
These assumptions are proven to be false, as the coupling requires long reaction times that 
drastically decrease protein stability and site specificity [87, 88]. Carboxyl groups can be 
PEGylated, but only when amines are not present, virtually eliminating the use with 
proteins and peptides [89]. Like carboxyl groups, hydroxyl groups are only suitable for 
PEGylation for uses in non-peptide moieties such as matrices for chromatography and 
biocompatible surfaces [90]. The second generation PEGylation methods have potential to 
be effective, site-specific coupling mechanisms, but each method is limited to its own 
specifications resulting in a narrow range of proteins that can be modified.  
 
While PEGylation has a countless number of unique functionalities, it presents major 
drawbacks in modifying biotherapeutic proteins due to the heterogeneity of PEG resulting 
in characterization and purification limitations. Along with the characterization and 
purification, being able to maintain native protein activity, while improving in-vivo drug 
half-life is crucial in developing novel modifier of biotherapeutics. 
 
1.4. Peptoids (Poly-N-Substituted Glycines) 
 
 
Peptoids, or N-substituted glycines, are synthetic peptidomimetic oligomers that 
structurally resemble 𝛼-peptides, but have side chains attached to the amide groups on the 
backbone instead of the 𝛼-carbon as in peptides (Figure 1.1.) [91]. This structural 
modification generates an achiral backbone that eliminates the potential for hydrogen 
bonding, resulting in a protease-resistant polymer that exhibits good cell permeability and 
protein binding characteristics resembling that of more “drug-like” molecules [92]. In 
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peptides, hydrogen bonding occurs between the amide hydrogen and the carbonyl oxygen 
on the backbone, which, although critical for the formation of distinct secondary structures 
can result in the denaturation of the molecule. The backbone hydrogen bonds are 
weakened and susceptible to breakage when exposed to extreme conditions (heat, 
ultraviolet radiation, strong acids or bases, organic solvents, and enzymes) causing the 
denaturation of the peptide’s secondary structure [93]. This is unfavorable because many 
peptides rely on the secondary structure to determine functionality and bioactivity; 
therefore, the high-sensitivity of peptides to denaturation presents a major drawback for 
the usage as biotherapeutics [94]. 
 










1.4.1. Peptoid Synthesis 
 
 
Peptoids can be produced via a sequence-specific, solid-phase synthesis method 
comparable to that of peptides. Unlike peptide synthesis, where submonomers must be 
protected prior to addition, peptoid synthesis allows for the precise addition of 
unprotected submonomers greatly simplifying the process. The submonomer method is a 
highly efficient, low cost synthesis technique that allows for the addition of a wide variety 
of side chains as primary amines. Using a solid-phase support (Ex: Rink Amide Resin), 
submonomers are added from carboxylic to amine termini via a submonomer “cycle” made 
up of two-steps: (1) acylation and (2) amination (nucleophilic substitution) (Figure 1.2.) 
[91]. The first reaction of the submonomer cycle, acylation, adds an activated carboxylic 
acid derivative onto a receptive amine generating a tertiary amide bond. In general, 
bromoacetic acid and diisopropylcarbodiimide (DIC) are used for acylation. The 
bromoacetic acid is activated by DIC separately, and then added to the solid-phase support 
[95]. The second step in the cycle, amination, involves the nucleophilic displacement of the 
halide (typically bromine) by a primary or N-terminal secondary amine (side-chain). As the 
halide group is removed from the haloacetamide, the primary nitrogen submonomer 
attacks the alpha-carbon forming an ammonium salt. The halide ion then removes 
hydrogen from the ammonium salt producing hydrogen bromide [95, 96]. The amination 
step creates the molecular diversity that is present in peptoids due to the thousands of 









To overcome stability and half-life issues seen in most biotherapeutic proteins, researchers 
in the last decades have worked to develop new modification and delivery techniques. 
Although many of these newly developed delivery methods, such as the use of 
nanoparticles and lysosomes, show great promise, their use is still hampered by an 
increase in protein aggregation, ultimately decreasing drug efficacy. The newly discovered 
modification methods commonly use well-known coupling chemistries for the 
incorporation of a wide range of molecules to increase resistance to enzymatic 
degradation. However, as seen in PEGylation, many of these modifications result in the 
formation of heterogeneous protein conjugates that have a decrease in native protein 
activity, and require inefficient, costly purification methods. Thus, there is a critical need to 
develop a site-specific protein modification method that can produce homogeneous 
products to enhance bioavailablity and efficacy of therapeutic proteins.  
 
Peptoids are attractive as novel biomimetic polymers that can potentially be used in 
therapeutic protein modifications and delivery systems because of their resistance to 
17 
 
degradative enzymes, great cell permeability, and low immunogenicity [97]. The peptoid 
sequence is fully customizable through the addition of side chains with various chemistries. 
By incorporating side chains with specific functional groups into the sequence, common 
coupling chemistries can be used to cross-link the peptoid to peptides, proteins, 
nanoparticles, and other molecules [98]. Protein modifications involving sequence specific 
peptoids offers a promising means for overcoming stability and absorption issues 
commonly displayed by current biotherapeutics.  
 
Like PEGylation, the challenge still lies in forming homogenous products that maintain 
native protein bioactivity and conformation [99]. Since PEG groups have traditionally 
shown an increased stability to serum enzymes, but failed to produce homogeneous 
products, increased efforts have been to find a PEG alternative. N-methoxyethylglycine 
(NMEG) is a hydrophilic peptoid monomer that resembles the structure of PEG (Figure 
1.3.). The NMEG monomer can be produced by incorporating 2-methoxyethylamine side 
chains onto the peptoid backbone via the solid-phase synthesis method. The NMEG 
peptoids can be covalently attached to a desired molecule by site-specific coupling 
reactions, called NMEGylation [100]. Previous research shows that, like PEG groups, 
oligoNMEGs are promising as antifouling agents. NMEGylated protein conjugates of varying 
lengths showed a decrease in serum protein adsorption and a resistance to cell attachment 
for an extended period in vitro, both desired characteristics for use as a biotherapeutic 
[101]. As predicted and proven in recent studies, the NMEGylation of polypeptides resulted 
in an increase in desirable properties such as increased water solubility, hydrophobicity, 
and serum stability, while also maintaining the original binding affinity of the peptide to its 
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target [100]. These studies for the NMEGylation of peptides/proteins are promising, 
however, the true efficacy of this method needs to be explored further.  
 
 
Figure 1.3. Structural comparison between NMEG and PEG. 
 
1.5. Green Chemistry 
 
 
Chemistry has played, and will continue to play an important role in nearly every aspect of 
modern life, from pharmaceutical manufacturing to polymer development. Over the last 
three decades, green chemistry has been an emerging field internationally, supported 
through the creation of hundreds of governmental initiatives working to achieve 
sustainability [102]. Green Chemistry is originally defined as the “design of chemical 
products and processes to reduce or eliminate the use and generation of hazardous 
substances” and can be characterized by the careful planning and molecular design of 
experiments [103]. In 1998, Paul Anastas and John Warner, often known as the “fathers” of 
the Green Chemistry field, developed The Twelve Principles of Green Chemistry as a 
framework for the design of new chemical processes [104]. This framework focuses to 
reduce potential hazards, including toxicity, physical hazards, and environmental hazards, 
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across all stages in chemical processes [105]. The first principle, waste prevention, involves 
the reduction in the amount of waste produced. Since the amount of waste produced is 
often directly correlated to many of the remaining principles, it is considered to be the 
most impactful in developing a “Green” chemical process. Chemical companies have started 
investing in waste management techniques, in part due to the increased public awareness 
in the environment, but mainly because of a governmental increase in the cost of waste 
removal, amounting to nearly 40% of the overall production costs [106]. When analyzing 
the waste management process, it is important to look at the efficiency of the chemical 
reaction taking place. Yield, chemical selectivity, atom efficiency, energy spent, solvent 
usage, and renewable raw materials are all impactful to the overall efficiency of the 
reaction and can be managed to decrease waste production [107, 108, 109, 110]. 
 
1.5.1. Green Chemistry Oxidation 
 
 
Inspired by The Principles of Green Chemistry, the work of researchers has focused on 
developing “greener” chemical reactions that reduce or eliminate the use and generation of 
toxic chemicals. The original focus has been on waste elimination, or what is known as the 
E factor (environmental factor). The E factor is a metric used to quickly assess the 
environmental effect of manufacturing processes, and is typically measured in kg waste per 
kg product [111]. To determine the true E-factor value and amount of waste produced, it is 
important to look into the stoichiometric equation for the overall process [112]. Along with 
the E factor, in 1991, using what is known as “atom economy”, scientists began 
investigating the reaction efficiency and where in the process the waste content originates. 
By analyzing waste production of inefficient processes (high E factor values), they found an 
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increased amount of organic salts, metal (Na, Mg, Zn, Fe) and metal hydride (LiAlH4, 
NaBH4) reducing agents and oxidants such as permanganate, manganese dioxide, and 
chromium (VI) reagents [113]. These results prove the important role that catalysis and 
solvent choice play in the development of green chemistry reactions [114].  
 
Traditionally, catalytic oxidation of alcohols (primary, secondary, allylic, propargylic, etc) 
to aldehydes, ketones, and carboxylic acids require the incorporation of many harsh 
reagents. Chromium (VI) oxides are well-known oxidants for the conversion of primary and 
secondary alcohols to aldehydes and ketones; however, this method requires the use of 
harsh organic solvents such as pyridine, dimethylformamide (DMF) with sulfuric acid, and 
others [115, 116, 117, 118]. The handling of chromium (VI) compounds is crucial due to its 
chronic toxicity and contamination of product. A study of workers exposed to chromium 
(VI) compounds have reported the development of asthma and other signs of respiratory 
distress, accompanied by a 20% decrease in forced expiratory volume of the lungs [119].  
 
The Swern oxidation, typically using dimethylsulfoxide (DMSO), oxalyl chloride, and 
trimethylamine in methylene chloride solvent does not produce heavy metal waste 
products, thus, making it a more environmentally friendly option [120]. However, 
drawbacks still exist in that oxalyl chloride is known to have toxic and corrosive properties, 
and methylene chloride is carcinogenic, hepatopathic, and neuropathic [121]. Other 
methods, such as the use of manganese dioxide (MnO), can oxidize allylic and benzylic 
alcohols, but are still faced with hazardous and toxic reagents, and the potential for 
residual metal contamination [122].  
21 
 
1.5.2. Bleach/TEMPO Oxidation 
 
 
The oxidation of primary alcohols to aldehydes and carboxylic acids is a fundamental 
transformation in organic chemistry. To create a more green chemistry oxidation method 
researchers have been investigating the use of nitroxyl radicals and transition metal salts. 
Both nitroxyl radicals tetramethylpiperidine-N-oxyl (TEMPO) radical and phthalimide-N-
oxyl (PINO) radical in the presence of small amounts of manganese (II) nitrate and cobalt 
(II) nitrate have displayed excellent results in the aerobic oxidation of benzyl alcohols to 
aldehydes and carboxylic acids [123]. However, the oxidation with these reagents is limited 
when dealing with less reactive aliphatic and allylic alcohols [124].  
 
The development of Anelli’s oxidation procedure has proven that aliphatic primary 
alcohols can be oxidized into aldehydes and carboxylic acids in a more efficient, green 
chemistry manner, by reacting the alcohol with a dichloromethane-water mixture 
containing bleach (sodium hypochlorite) in the presence of sodium bicarbonate, potassium 
bromide, and a catalytic amount of TEMPO free radical [125, 126]. TEMPO free radical 
serves as the primary oxidant for the transformation of alcohols into aldehydes by forming 
reactive oxoammonium salts. The secondary oxidant, sodium hypochlorite, is typically used 
to activate the TEMPO free radical by forming the oxoammonium salt, but subsequently 
plays a major role as the primary oxidant in the conversion of aldehydes to carboxylic 
acids. Typically, the reaction is done in an excess of sodium hypochlorite and a phase-
transfer catalyst forming to form a high yield of carboxylic acid [127]. However, by 
eliminating the phase-transfer catalyst and lowering the amount of sodium hypochlorite 
used the oxidation can produce aldehydes with low reaction times [128]. This modified 
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version of Anelli’s procedure allows for the fast, efficient, and low-cost oxidation of primary 
alcohols to aldehydes.   
 
2. Research Rationale  
 
While knowledge of different types of protein delivery systems and modification methods 
has grown in the last decades, the difficulty in characterization, susceptibility to enzymatic 
degradation, loss of stability and bioactivity, and economic costs continue to hinder them 
as viable treatment options. Thus, there is a critical need to develop a post-translational 
modification method that produces homogeneous conjugates that can be easily 
characterized and purified. This technique should increase protein resistance to enzymatic 
degradation and maintain native protein stability and bioactivity. The covalent attachment 
of NMEG-peptoids (NMEGylation) is a promising method to achieve this goal due to its 
favorable properties, such as an increase in water solubility and serum stability. It is 
believed that NMEGylation can fix the heterogeneity issues seen in PEGylation by 
modifying proteins in a site-specific manner. Unlike PEG-conjugates, NMEG peptoids allow 
for the precise positioning of specific chemical functional groups for attachment to reactive 
amino acids on the protein.  
 
The overall goal of this project is to develop a protein modification method that improves 
the serum stability and efficacy of biotherapeutic proteins to be used as potential treatment 
options. We hypothesize that the NMEGylation of a target protein will result in the 
production of a homogenous protein-peptoid conjugate that withstands enzymatic 
degradation and displays native protein conformation and activity. The modification will 
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occur through the cross-linkage, via reductive amination, of an aldehyde functional group 
on the peptoid and primary amines, namely lysine, on the surface of the protein. Due to the 
expensive and instable nature of commercially available aldehyde side chains, we will 
implement a modified Anelli’s oxidation method for the green chemistry oxidation of a 
primary alcohol peptoid side chain into the desired aldehyde functional group (Figure 2.1.). 
To minimize waste production and the use of toxic reagents, only sodium hypochlorite 
(bleach) and TEMPO free radical will be utilized for the oxidation reaction.  
 
Figure 2.1. Schematic for overall protein modification with NMEG peptoid (JLR-1).  
 
The hypothesis was supported by completing the following aims: 
 
 
1. Investigate the Green Chemistry oxidation of peptoid.  
We hypothesize that the oxidation using only bleach and TEMPO free radical will form 
the desired aldehyde side chain. The oxidation of primary alcohols occurs in two main 
steps, first to an aldehyde, then to a carboxylic acid. It is believed that by altering 
chemical kinetics, the oxidation can be stopped after the first step, forming a stable 
aldehyde group. It is believed that the concentration of bleach and reaction time plays a 
major role in the level of oxidation that occurs. LC-MS and MALDI-TOF mass 
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spectrometry will be used to determine the level of oxidation, and to confirm the 
formation of a stable aldehyde side chain.  
2. Investigate the cross-linkage of the NMEG peptoid to a target protein.  
We hypothesize that, in the presence of a reducing agent, the NMEG peptoid can be 
cross-linked to a target protein. The aldehyde group on the peptoid can be reacted, via 
reductive amination, with primary amines of lysines on the protein. Due to the 
abundance of lysine amino acids, it is predicted that multiple peptoid molecules will 
cross-link to the protein, drastically improving the ability of the protein to withstand 
protease degradation. By performing the reaction at physiological conditions, it is 
believed that the native activity and conformation of the protein will be maintained. 
Analytical HPLC and MALDI-TOS mass spectrometry will be used to confirm the cross-
linkage of peptoid to protein. Tricine SDS-PAGE gel and trypsin degradation assays will 
be performed to assess enzymatic resistance and protein stability.  
 
3. Materials  
 
MBHA rink amide resin was purchased from NovaBiochem (Gibbstown, NJ). The amine 
sub-monomer tert-butyl N-(4-aminobutyl) carbamate was purchased from CNH 
Technologies Inc. (Woburn, MA), 2-methoxyethylamine and ethanolamine were purchased 
from Acros Organics (Pittsburgh, PA). Piperidine was purchased from Sigma-Aldrich (St. 
Louis, MO). Sodium hypochlorite came from original Clorox™ purchased at Walmart 
(Bentonville, AR). 2,2,6,6-Tetramethylpiperidinooxy (TEMPO, free radical) was purchased 
from BeanTown Chemical Corporation (Hudson, NH). Sodium cyanoborohydride was 
purchased from Alfa Aesar (Haverhill, MA). All other reagents and consumables were 
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4.1. Peptoid Synthesis 
 
 
Peptoids were synthesized via the solid-phase submonomer method on MBHA rink amide 
resin [91]. Initially, the resin was swelled with dimethylformamide (DMF), then the Fmoc 
protection group was removed by two separate incubations in 20% piperidine solutions in 
DMF for 30 seconds and again for 12 minutes. The resin’s secondary amine was acylated 
with a fresh solution of 0.4 M bromoacetic acid and N,N’-diisopropyl carbodiimide (DIC) at 
a ratio of 4.25:0.8, mixing for 1 minute, forming a tertiary amine bond. The amine side 
chains were attached via nucleophilic displacement at concentrations ranging from 0.5-1.0 
M in DMF depending on the side chain. The two-step submonomer cycle was repeated until 
the desired sequence was obtained (Figure 5.1.). The peptoid was cleaved from the resin by 
mixing with 95% trifluoroacetic acid (TFA), 2.5% water, and 2.5% triisopropylsilane on an 
orbital shaker (Belly Dancer, Stovall Life Sciences, Greensboro, NC). The acid was removed 
using a Heidolph Laborota 4001 rotary evaporator (Elk Grove Village, IL), the peptoid was 
dissolved in a 50:50 acetonitrile:water solution, and dried to a powder using a Labconco 






4.2. Peptoid Purification 
 
 
The peptoid was reconstituted in a 25:75 acetonitrile:water solution and purified using a 
Waters Delta 600 preparative reversed-phase high performance liquid chromatography 
(HPLC) (Milford, MA) with a Duragel G C18 150 x 20 mm column (Peeke Scientific, Novato, 
CA). Due to the hydrophilic nature of the NMEG peptoid, equilibration times were extended 
from 20 minutes to 60 minutes, the injection volume was reduced to 1.2 mL per injection, 
and a 10-minute delay following injection was necessary prior to the linear gradient of 0-
65% solvent B (94.9% acetonitrile, 5% water, 0.1% TFA) in A (99.9% water, 0.1% TFA) 
over 65 minutes. Peptoids were confirmed to be >98% pure via analytical HPLC (Waters 
2695 Separation Module) with a Duragel G C18 150 x 2.1 mm column (Peeke Scientific, 
Novato, CA) using a gradient of 5-95% solvent D (99.9% acetonitrile, 0.1% TFA) in C 
(99.9% water, 0.1% TFA) over 30 minutes. Purified peptoid fractions were combined, 
lyophilized into a powder, and stored at -20 °C.  
 
4.3. Peptoid Characterization  
 
 
Synthesis and purification of the desired peptoid sequences were confirmed via matrix 
assisted laser desorption/ionization time of flight (MALDI-TOF; Bruker, Billerica, MA) mass 
spectrometry using 2,5-dihydroxybenzoic acid as a matrix substance. The oxidation and 
cross-linkage products were confirmed via a combination of liquid chromatography-mass 





4.4. Oxidation of Alcohol to Aldehyde 
 
 
To form the desired aldehyde from the oxidation reaction, a stoichiometric equivalent 
amount (1:1) of sodium hypochlorite to peptoid was used. The reaction solution contained 
0.1% bleach, 1% of 1.4 M TEMPO free radical, and 25% peptoid in phosphate buffered 
saline (PBS). The concentrations of bleach and peptoid were varied to optimize reaction 
yield. The reaction time was varied from 0 to 3 hours at 23 °C and a pH of 7.4.  
 
 
4.5. Cross-linkage Reaction 
 
 
Prior to the oxidation reaction, a 2 M amine reducing agent was prepared by dissolving 
sodium cyanoborohydride in a 5 M NaOH solution and allowing it to incubate for 1 hour 
before use. A 10% protein and water solution was prepared by a ten-fold dilution of 4 
mg/mL protein solution. The 10% protein and sodium cyanoborohydride solutions were 
added to the oxidated peptoid reaction solution. The reaction time was varied from 0 to 4 
hours at 33 °C and a pH of 7.4. At hour increments, the reaction was assessed by analytical 
HPLC using a gradient of 5 to 95% solvent D (99.9% acetonitrile, 0.1% TFA) in C (99.9% 
water, 0.1% TFA) over 30 minutes. The reaction product at each time point was spotted 
and the cross-linkage was confirmed by MALDI-TOF.  
 
4.6. Trypsin Degradation 
 
 
The protein was dissolved in a 50 mM ammonium bicarbonate solution. A 500 mM 1,4-
Dithiothreitol (DTT) solution was added to the protein sample to a final concentration of 20 
mM (1:25 dilution), then incubated at 60 °C for 1 hour. A fresh solution of 1 M 3-
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indoleacetic acid (IAA) was prepared using 50 mM ammonium bicarbamate. The 1 M IAA 
solution was added to the reduced protein sample to a final concentration of 40 mM (1:25 
dilution) and allowed to incubate at room temperature for 30 minutes protected from light. 
The alkylation reaction was quenched by adding 500 mM DTT to a final concentration of 10 
mM (1:50 dilution). Trypsin solution was added to the sample to form a final protease to 
protein ratio of 1:30 to 1:100 (w/w). The final solution was incubated at 37 °C for 24 hours 
and stored at -20 °C to stop the digestion reactions. The digested fractions were analyzed 
using MALDI-TOF and a Tricine-SDS-PAGE gel.  
 
5. Results and Discussion 
 
5.1. Peptoid Sequence Rationale and Characterization 
 
 
Previous studies have shown that NMEGylation is a viable post-translational modification 
method to improve the desirable characteristics of biotherapeutic proteins. The peptoid 
sequences, referred to as JLR-1 and BiCK-5 (Figure 5.1a & 5.1b), each include five N-
methoxyethyl glycine (NMEG) side chains to improve the water solubility and serum 
stability of the target protein. Both, JLR-1, and BiCK-5, contain cysteine-like side chains on 
the C-terminus to enable covalent linkage to slide surfaces and other molecules. The 
hydroxyl-group on the ethanol side chain of JLR-1 can be oxidized into an aldehyde to 
enable the covalent linkage to amine groups on a target molecule. The lysine-like side chain 
of BiCK-5 provides a primary amine group that can be reacted with the aldehyde on JLR-1 
to test the efficiency of and optimize the cross-linkage reaction. MALDI-TOF (Figure 5.2.) 















































































5.2. Oxidation of Alcohol to Aldehyde  
 
 
The product formed during the oxidation of primary alcohols is directly affected by the 
amounts of oxidizing agents used, the reaction time, and the reaction temperature. A 
common issue that arises in the formation of aldehydes is that the oxidation reaction 
progresses too far, forming an unwanted carboxylic acid group. Thus, to form the desired 
aldehyde it is important to find the optimal bleach and TEMPO free radical concentrations, 
as well as an optimal reaction time.  
 
Initially, a solution containing 1% bleach and 1% TEMPO free radical was reacted with JLR-
1 for 3 hours at room temperature. The amount of sodium hypochlorite in the reaction was 
nearly 10x higher than the amount of peptoid used. LC-MS (Figure 5.4.) and MALDI-TOF 
(Figure 5.5.) results of this oxidation demonstrated the formation of the undesired 
carboxylic acid group on JLR-1. The LC-MS spectrum showed two main peaks at 6 and 7 
minutes, corresponding to the initial JLR-1 and JLR-1 with carboxylic acid, respectively. The 
mass spectrometry spectrum for the second peak confirmed the formation of the carboxylic 
acid group, shown by the peak at 825.5 m/z. Based on these results, we can conclude that 
the oxidation reaction of JLR-1, using 1% bleach, 1% TEMPO free radical, and a reaction 
time of 3 hours, fully progressed, passing the formation of an aldehyde, ultimately 






Figure 5.4. LC-MS spectrum for the oxidation of JLR-1 with 1% bleach at 3 hours. (Top) 





Figure 5.5. Mass spectrum for LC-MS of JLR-1 with 1% bleach at 3 hours.  
 
The amount of bleach used in the oxidation reaction was decreased 10-fold, forming nearly 
a 1:1 ratio of sodium hypochlorite to peptoid.  The reaction time was decreased from 3 
hours to 15 minutes, while the TEMPO free radical concentration, pH, and temperature 
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were kept constant. To determine the time at which oxidation occurs, the reaction solution 
was spotted for MALDI-TOF at time points of 0, 1, 5, and 15 minutes.  
 
As expected, no oxidation occurred at 0 minutes, shown by a single mass peak at 811 m/z 
(Figure 5.6.) representing an unoxidized peptoid. At 1 minute, the MALDI-TOF spectrum 
(Figure 5.7.) began showing a peak at 809-810 m/z indicating the formation of the desired 
aldehyde group on JLR-1. The intensity of this peak (809-810 m/z) and the sodiated 
version (831-832 m/z) increased at the 5-minute mark (Figure 5.8.). By 15 minutes, the 
MALDI-TOF results (Figure 5.9.) showed a drastic increase in the intensity of the mass peak 
for the newly formed aldehyde peptoid. The sodiated version of this peak displayed an 

















































































































































Figure 5.9. MALDI-TOF spectrum for JLR-1 with 0.1% bleach, 1% TEMPO after 15 minutes. 
 
As hypothesized, the primary alcohol of JLR-1 was oxidized, using bleach and TEMPO free 
radical, and the desired aldehyde group was formed. The amount of bleach and reaction 
time was proven to be critical in controlling the reaction kinetics. By controlling these 
kinetics, the oxidation reaction was essentially ‘stopped’ at the aldehyde, instead of 
progressing to the formation of a carboxylic acid. Along with a reduction in reaction time, a 
stoichiometrically equivalent amount of sodium hypochlorite to peptoid is beneficial in 






















































5.3. Cross-linkage (NMEGylation) 
 
 
The reductive amination reaction was tested by cross-linking the JLR-1 and BiCK-5 
peptoids. The aldehyde group on JLR-1 covalently attaches to the primary amine on BiCK-5 
in the presence of a strong reducing agent (sodium cyanoborohydride). The reaction 
product was analyzed by MALDI-TOF, which shows a mass peak at 1670 m/z that could 
potentially indicate a successful cross-linkage (Figure 5.10.). The expected molecular 
weight of the JLR-1 and BiCK-5 cross-linkage is 1631 Da; however, the 1670 m/z peak 
could represent the cross-linked peptoid in the presence of a potassium ion (+39 m/z). 
Unfortunately, the 1670 m/z peak could also be due to the undesired reaction between 
thiol groups on the cysteines of both peptoids. This thiol linkage results in an expected 
peptoid conjugate mass of 1647-1648 Da, which if sodiated, could also be representative of 




Figure 5.10. MALDI-TOF spectrum for the potential cross-linkage of JLR-1 and BiCK-5. 
 
 
One issue observed in the cross-linkage between peptoids is the similarity in molecular 
weights between the two molecules. The molecular weight of the aldehyde version of JLR-1 
(809 Da) was only 29 Da less than BiCK-5 (838 Da). Other issues arise due to the 
complexity in the cross-linkage reaction, the potential for unwanted reactions, and the 
presence of salts (sodium, potassium, etc), making the characterization, especially via 
MALDI-TOF, extremely difficult. 
 
In order to overcome the issues observed with BiCK-5, the protein bovine cytochrome c 
was chosen for the cross-linking reaction with JLR-1. Cytochrome c has an abundance of 
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lysine amino acids, 18, that could be modified in the amination reaction, increasing the 
chances for successful NMEGylation. Immediately following the oxidation of JLR-1, bovine 
cytochrome c and sodium cyanoborohydride were added to the peptoid solution and 
allowed to react for 4 hours at physiological conditions (temperature of 33 °C and a pH of 
7.4). The analytical HPLC results demonstrate a shift in the HPLC peaks that increases in 
intensity as time progresses (Figure 5.11.). The initial cytochrome c (Figure 5.11A) and 
JLR-1 (Figure 5.11B) peaks at 17 and 13.5 minutes, respectively, have shifted to the 
modified protein peak (Figure 5.11C) at ~10 minutes. We predict that this shift represents 
the formation of peptoid-protein conjugates through the successful cross-linkage of JLR-1 
to cytochrome c. As reported in the literature, NMEGylation increases the water solubility 
of the protein; therefore, the modified protein would be expected to elute from the column 
faster than the original protein did.  
 
Figure 5.11. Analytical HPLC spectra for (A) cytochrome c protein (B) oxidized JLR-1 
peptoid (C) cross-linkage of cytochrome c with JLR-1 at 0 (black), 1 (dark blue), 2 (green), 3 
(light blue), & 4 (pink) hours (D) combination of A-C. 
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The MALDI-TOF results (Figure 5.12.) for the reaction also indicate that the protein was 
successfully modified; however, the extent of modification is still unclear. It is proposed 
that the modification occurred on several lysines, producing a mixture of conjugate 
polymers that reduce the intensity of the modified cytochrome c peak (12,232 m/z). The 
number of lysines that are accessible for modification is dependent on the three-
dimensional structure of the protein. Another issue arises with the possibility of JLR-1 
forming disulfide bonds with the heme prosthetic group of cytochrome c. The heme group 
serves to organize the protein structure of cytochrome c. It is possible that by binding with 
heme, JLR-1 interfered with the formation of native protein structure, resulting in an 
unexpected number of lysines to be modified.  
 
 

































































6. Conclusion and Future Work 
 
The need for accurate, effective, and long-lasting biotherapeutic treatment options has led 
to the development of more intricate modification methods and drug delivery systems. 
Biotherapeutics require evolutionary advancements in serum stability and drug efficacy to 
be beneficial in future medicinal applications. The challenge lies in developing modification 
methods that form homogeneous products in a manner that native protein conformation 
and activity is maintained. We believe that the use of peptoids for the modifications of 
biotherapeutic proteins provides a propitious mode to achieve such goals.  
 
We were able to successfully design a green chemistry oxidation method that modified a 
peptoid side chain to be used as a reactive functional group in the NMEGylation of a target 
protein. We found that by altering the reaction time and concentrations of reagents, the 
reaction rate can effectively be controlled and the desired oxidative product can be 
obtained. We demonstrated this ability by forming a stable aldehyde functional group from 
the oxidation of a primary alcohol using only bleach and TEMPO free radical as oxidative 
agents. Initially, higher bleach concentrations and longer reaction times caused the 
reaction to by-pass the aldehyde, and directly form a carboxylic acid. Through a ten-fold 
dilution in bleach concentration and a reduction in reaction time to 15 minutes, we were 
able to produce the desired aldehyde. Sodium hypochlorite activates the TEMPO free 
radical which serves as the main oxidant for the reaction. We believe that the reduction in 
sodium hypochlorite limited the amount of TEMPO free radical that was activated; 
ultimately stopping the reaction at the aldehyde. It is important to note that although the 
reaction was successful in producing the desired product, there is still room for 
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improvement in the efficiency of the reaction. It would be interesting to assess the effect of 
lowering the TEMPO concentration on aldehyde formation. The ratios of TEMPO and bleach 
can be varied to optimize the aldehyde production. If the amount of bleach and TEMPO can 
be reduced even further, then it would make it more environmentally friendly, improving 
the E-factor rating of the reaction. Also, instead of going straight into the cross-linkage it 
would be intriguing to investigate purification methods, and stability tests for the newly 
formed aldehyde peptoid.  
 
We have studied the attachment of NMEG peptoid to a target protein to overcome stability 
and absorption issues displayed by current biotherapeutics. We proposed that an aldehyde 
group on the peptoid can be reductively aminated with primary amines on the target 
protein to form a homogeneous NMEG peptoid-protein conjugate. It is believed that this 
conjugate will carry some of the desirable properties seen in PEG and NMEG monomers, 
such as increased water solubility and resistance to enzymatic degradation. We have 
evaluated the use of NMEG peptoids for site-specific modification to biotherapeutic 
proteins; however, are still limited in characterization techniques. Initially, the amination 
reaction was tested between two peptoids, JLR-1 and BiCK-5, but due to similarities in 
molecular weights the product could not be fully characterized. It is believed that the cross-
linked product shown on MALDI-TOF is an unwanted disulfide linkage formed between the 
cysteine groups on both peptoids. To eliminate this possibility, our lab will further 
investigate the synthesis and usage of peptoids without cysteine side chains. Also, the 
molecular weight disparity can be increased by synthesizing peptoids with various NMEG 
chain lengths (n=5, 10, 15).  
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We have demonstrated that the NMEGylation of target proteins results in many of the same 
limitations that currently hinder PEGylation as a viable modification method. When 
evaluating the cross-linkage of JLR-1 to cytochrome c, the mass spectrometry results 
indicated that a cross-linkage between the two molecules possibly occurred, but the degree 
of modification (number of lysines modified) could not be determined. From the MALDI-
TOF results in Figure 3.10., we believe that the number of lysines modified with peptoid 
varied from molecule to molecule, forming a heterogeneous mixture of peptoid-protein 
conjugates. The covalent bonding between thiol functional group on the cysteine side chain 
of JLR-1 and the heme group of cytochrome c may play an important role in the 
characterization issues. Any factor, whether it’s the binding to heme, or a change in 
reaction conditions, can cause the protein to unfold, revealing hidden amino acids that are 
now able to react. Depending on the reaction environment, each individual protein 
molecule may undergo a unique conformational change, resulting in a wide array of 
reactive groups. It is important to note that although heterogeneous conjugates were 
potentially formed, the viability of NMEGylation as a biotherapeutic protein modification 
method needs to be further investigated. It would be interesting to complete a more 
thorough study on the cross-linkage of various NMEG peptoids to different target proteins. 
To avoid potential heme binding, several target proteins, such as myoglobin, can be used in 
place of cytochrome c. Other peptoid sequences can be adopted to pursue different 
conjugation chemistries with the target protein. Trypsin assays and Tricine-SDS-PAGE gel 
electrophoresis can be used to further analyze the reaction products formed and to test 
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